Fuller & Thaler Asset Management
TPST icon

Fuller & Thaler Asset Management’s Tempest Therapeutics TPST Stock Holding History

Fuller & Thaler Asset Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-72
Closed -$1.5M – 782
2016
Q3 		$1.5M Sell
72
-2
-3% -$36.2K 0.02% 217
2016
Q2 		$1.13M Buy
+74
New +$1.69M 0.02% 228

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CC
CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fuller & Thaler Asset Management's TPST Position: Q4 2016 in Review

Fuller & Thaler Asset Management sold out of Tempest Therapeutics (TPST) in Q4 2016, closing a stake of 72 shares — an estimated $1.5M sold.

Fuller & Thaler Asset Management first reported a position in TPST in Q2 2016 and held it in 2 quarters. The position peaked at $1.5M in Q3 2016. 84 funds tracked by Wall St. Rank hold TPST as of Q4 2016.

  • Fuller & Thaler Asset Management reported no remaining Tempest Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 72 Tempest Therapeutics shares in Q4 2016, an estimated $1.5M.
  • Fuller & Thaler Asset Management first reported a position in Tempest Therapeutics in Q2 2016 and held it in 2 quarters.
  • Fuller & Thaler Asset Management's Tempest Therapeutics position peaked at $1.5M in Q3 2016.
  • 84 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2016.

Based on Fuller & Thaler Asset Management's 13F filing for Q4 2016, filed 7 Feb 2017.